NMBAs in Ventilated Sepsis: No Mortality Signal, Longer ICU Stay, More VAP
This propensity-adjusted national registry analysis gives critical care pharmacists sepsis-specific, real-world data on continuous neuromuscular blocking agent (NMBA) infusion, a question previously informed mainly by acute respiratory distress syndrome (ARDS) trials.
📅 Journal publication: Nov 2, 2026·Last updated: Nov 6, 2026
neuromuscular blocking agentscisatracuriumvecuroniumrocuroniumsepsismechanical ventilationventilator-associated pneumoniapropensity score matchinginverse probability of treatment weightingICU length of stayobservational cohortcritical careCritical Care / ICU
Background Information
NMBA use in sepsis raises ICU stay and pneumonia risk.
The impact of neuromuscular blocking agents (NMBAs) on outcomes in septic patients needing mechanical ventilation is unclear and impacts ICU management strategies. NMBA use did not affect in-hospital mortality but led to longer ICU stays (3 days longer) and increased ventilator-associated pneumonia (8.6% vs. 4.5%). The study highlights potential risks of NMBA use in sepsis patients, including longer ICU stays, suggesting cautious use in practice. NMBA use in sepsis increases ICU stay and pneumonia risk without mortality benefit.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Nam H, Lim SY, Lee KJ, Lee YJ, Ko RE, Suh GY, Cho WH, Hyun DG, Lim CM, Park S, Korean Sepsis Alliance (KSA) Investigators
Citation:Nam H, Lim SY, Lee KJ, et al. Impact of Neuromuscular Blocking Agents on Hospital Outcomes in Mechanically Ventilated Patients With Sepsis: Propensity Score Analyses of A Nationwide Sepsis Cohort. Journal of Korean medical science. 2026;41(42):e284. doi:10.3346/jkms.2026.41.e284